Advanced technology
for preventing infections
Differentiating your Medical devices
Interim report Q2 2024
Bactiguard Holding AB (publ) publishes its interim report for the second quarter on Tuesday 16 July 2024 at 07:00 CET.
In connection with this, Bactiguard will host an audiocast for investors, analysts, and media at 11:00 CET. CEO Christine Lind will present the report and answer questions together with CFO Patrick Bach.
Bactiguard in brief
Bactiguard is a global MedTech company developing safe and biocompatible technology to prevent medical device related infections. The company’s unique and patented technology prevents bacterial adhesion and biofilm formation on medical devices.
Bactiguard’s infection prevention solutions decrease patient suffering, save lives, and unburden healthcare resources while also fighting against antimicrobial resistance, one of the most serious threats to global health and modern medicine.
Bactiguard operates through license partnerships with leading global MedTech companies and also has a portfolio of wound management products.
Redefining infection prevention
The Bactiguard Technology
Bactiguard’s unique infection prevention coating technology is safe and biocompatible, and significantly reduces the risk of medical device related infections. Approved for both short- and long-term use.
License Partnerships
Bactiguard operates through license partnerships with leading global MedTech companies that apply the technology to their medical devices and sell them under their own brand or co-branded with Bactiguard.
Wound Management
Bactiguard’s Wound Management offering includes Hydrocyn aqua, an innovative wound care product enabling wound healing and preventing infection and a wide range of surgical sutures.
